56R0 Stock Overview
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
NanoVibronix, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.68 |
52 Week High | US$1.21 |
52 Week Low | US$0.63 |
Beta | 1.27 |
1 Month Change | -16.67% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -97.62% |
Recent News & Updates
Recent updates
Shareholder Returns
56R0 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -1.5% | -0.5% | -0.3% |
1Y | n/a | -10.1% | 2.8% |
Return vs Industry: Insufficient data to determine how 56R0 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 56R0 performed against the German Market.
Price Volatility
56R0 volatility | |
---|---|
56R0 Average Weekly Movement | 7.7% |
Medical Equipment Industry Average Movement | 4.5% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 56R0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 56R0's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 13 | Brian Murphy | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
NanoVibronix, Inc. Fundamentals Summary
56R0 fundamental statistics | |
---|---|
Market cap | €1.90m |
Earnings (TTM) | -€3.45m |
Revenue (TTM) | €2.12m |
0.9x
P/S Ratio-0.6x
P/E RatioIs 56R0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
56R0 income statement (TTM) | |
---|---|
Revenue | US$2.28m |
Cost of Revenue | US$746.00k |
Gross Profit | US$1.54m |
Other Expenses | US$5.25m |
Earnings | -US$3.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.33 |
Gross Margin | 67.32% |
Net Profit Margin | -162.55% |
Debt/Equity Ratio | 0% |
How did 56R0 perform over the long term?
See historical performance and comparison